The BRCA-P study will investigate if using Denosumab is a safe and effective way of preventing breast cancer.
Participants on BRCA-P will receive a study medication injection (Denosumab or placebo) every six months for five years. This study is a randomised, double-blind, placebo-controlled study, which means participants, and their study doctor, will not know if they are receiving the Denosumab or placebo (a treatment that looks just like the active medication, but has no effect).
If you are a woman between 25 and 55, with a known BRCA1 gene mutation, no current or previous breast cancer diagnosis, and not planning to have, or have not already completed surgery to remove both breasts, this trial might be suitable for you.
Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at email@example.com
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to firstname.lastname@example.org
Subscribe for updates & stay in the loop with new studies.